Giuseppe Curigliano

Giuseppe Curigliano

UNVERIFIED PROFILE

Are you Giuseppe Curigliano?   Register this Author

Register author
Giuseppe Curigliano

Giuseppe Curigliano

Publications by authors named "Giuseppe Curigliano"

Are you Giuseppe Curigliano?   Register this Author

100Publications

1859Reads

50Profile Views

Breast implant-associated anaplastic large cell lymphoma: A comprehensive review.

Cancer Treat Rev 2020 Jan 13;84:101963. Epub 2020 Jan 13.

Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Haemato-Oncology, University of Milano, Milan, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2020.101963DOI Listing
January 2020

Tumour infiltrating lymphocytes and correlation with response to intensified platinum-based chemotherapy in BRCA-like tumours.

Eur J Cancer 2020 Jan 20. Epub 2020 Jan 20.

European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.12.004DOI Listing
January 2020

Is Explanation a Marketing Problem? The Quest for Trust in Artificial Intelligence and Two Conflicting Solutions.

Public Health Genomics 2020 Jan 28:1-4. Epub 2020 Jan 28.

Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000506014DOI Listing
January 2020

Corrigendum to "Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors" [Cancer Treatm. Rev. 74 (2019) 21-28].

Cancer Treat Rev 2019 12 6;81:101913. Epub 2019 Nov 6.

Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2019.101913DOI Listing
December 2019

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

N Engl J Med 2019 Dec 11. Epub 2019 Dec 11.

From M.D. Anderson Cancer Center, Houston (R.K.M., G.H.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (S. Loi); the Royal Marsden NHS Foundation Trust, London (A.O.), and Edinburgh Cancer Research Centre, Edinburgh (D.C.) - both in the United Kingdom; Winship Cancer Institute, Atlanta (E.P.); Sarah Cannon Research Institute/Tennessee Oncology-Nashville (E.H.) and Vanderbilt University Medical Center (V.A.), Nashville; University of California, Los Angeles, Medical Center-Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H., D.S.), and Stanford Comprehensive Cancer Institute, Palo Alto (M.P.) - both in California; Dana-Farber Cancer Institute, Boston (N.U.L., I.K., E.P.W.); University of Colorado Cancer Center, Aurora (V.B.); Duke Cancer Institute, Durham (C.A.), and University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill (L.A.C.) - both in North Carolina; University Health Network, Princess Margaret Cancer Centre, Toronto (P.L.B.), and British Columbia Cancer, Vancouver (K.G.) - both in Canada; Hospital Universitario Vall D'Hebron, Barcelona (M.O.); Sygehus Lillebaelt-Vejle Sygehus, Vejle, Denmark (E.J.); Centre Léon Bérard, Lyon, France (T.B.); Rambam Health Care Campus, Haifa, Israel (S.S.S.); Universitaetsklinikum Hamburg-Eppendorf, Hamburg (V.M.), and German Breast Group, Neu-Isenburg (S. Loibl) - both in Germany; Hospital Cuf Descobertas R. Mário Botas, Lisbon, Portugal (S.B.); Cliniques Universitaires Saint-Luc, Brussels (F.P.D.); Third Medical Department, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials, and Cancer Cluster Salzburg, Salzburg, Austria (R.G.); Istituto Europeo di Oncologia, IRCCS, University of Milan, Milan (G.C.); and Seattle Genetics, Bothell, WA (M.C.P.-W., L.W., W.F.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1914609DOI Listing
December 2019

CDK4/6 inhibitors in breast cancer: one more step towards reduced mortality.

Lancet Oncol 2019 Dec 16. Epub 2019 Dec 16.

GBG Forschungs GmbH and Centre for Haematology and Oncology, Bethanien, Frankfurt, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30808-3DOI Listing
December 2019

Expression of tumor-associated antigens in breast cancer subtypes.

Breast 2019 Dec 12;49:202-209. Epub 2019 Dec 12.

Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy; Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.12.002DOI Listing
December 2019

Breast Cancer: Reimbursement Policies and Adoption of New Therapeutic Agents by National Health Systems.

Breast Care (Basel) 2019 Dec 24;14(6):373-381. Epub 2019 Sep 24.

Department of Breast Tumours, Cancer Institute Ion Chiricuta, Cluj-Napoca, Romania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000502637DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940432PMC
December 2019

Editorial: Optimizing treatment strategy in early breast cancer: less is more, or more is better?

Curr Opin Oncol 2019 Nov;31(6):469-471

IEO, European Institute of Oncology IRCCS.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000582DOI Listing
November 2019

Harmonizing gene signatures to predict benefit from adjuvant chemotherapy in early breast cancer.

Curr Opin Oncol 2019 Nov;31(6):472-479

IEO, European Institute of Oncology IRCCS.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000570DOI Listing
November 2019

Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside.

Eur J Cancer 2019 Nov 10;122:22-41. Epub 2019 Oct 10.

Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy; Department of Biosciences, University of Milan, Milan, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.08.013DOI Listing
November 2019

Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer.

Adv Exp Med Biol 2019 ;1168:9-30

Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-030-24100-1_2DOI Listing
November 2019

Biosimilars for breast cancer.

Expert Opin Biol Ther 2019 Oct 10;19(10):1015-1021. Epub 2019 Jul 10.

Division of Early Drug Development for Innovative Therapy, European Institute of Oncology IRCCS , Milan , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1638362DOI Listing
October 2019

Evaluating triptorelin as a treatment option for breast cancer.

Expert Opin Pharmacother 2019 Oct 9;20(15):1809-1818. Epub 2019 Sep 9.

Division of Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS , Milan , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1650020DOI Listing
October 2019

Are Biosimilars the Future of Oncology and Haematology?

Drugs 2019 Oct;79(15):1609-1624

Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-019-01193-yDOI Listing
October 2019

What therapies are on the horizon for HER2 positive breast cancer?

Expert Rev Anticancer Ther 2019 Sep 28;19(9):811-822. Epub 2019 Aug 28.

Division of Early Drug Development for Innovative Therapy, IEO, European Institute of Oncology IRCCS , Milan , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2019.1660164DOI Listing
September 2019

Treatment in real-life patients with HER2-positive metastatic breast cancer: What we learn from the KAMILLA trial?

Eur J Cancer 2019 Aug 21;117:1-4. Epub 2019 Jun 21.

European Institute of Oncology, IRCCS, Italy; University of Milano, Milano, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.04.028DOI Listing
August 2019

The evolving landscape of 'next-generation' immune checkpoint inhibitors: A review.

Eur J Cancer 2019 Aug 21;117:14-31. Epub 2019 Jun 21.

New Drugs and Early Drug Development for Innovative Therapies Division, IEO, European Institute of Oncology IRCCS, Milan, Italy; University of Milano, Department of Hematology and Hemato-Oncology, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.04.035DOI Listing
August 2019

Are all cyclin-dependent kinases 4/6 inhibitors created equal?

NPJ Breast Cancer 2019 29;5:27. Epub 2019 Aug 29.

1Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41523-019-0121-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715721PMC
August 2019

Targeting DNA Repair.

Handb Exp Pharmacol 2018;249:161-180

Early Drug Development for Innovative Therapy Division, European Institute of Oncology, Via Ripamonti, 435 20141, Milan, Italy.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/164_2017_31
Publisher Site
http://dx.doi.org/10.1007/164_2017_31DOI Listing
June 2019

Cancer Evolution as the New Frontier of Precision Medicine.

Handb Exp Pharmacol 2018;249:289-297

Division of Experimental Cancer Medicine, Istituto Europeo di Oncologia, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/164_2018_147DOI Listing
June 2019

Homologous recombination deficiency in triple negative breast cancer.

Breast 2019 Jun 20;45:15-21. Epub 2019 Feb 20.

Division of Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan, via Ripamonti 435, 20141, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, via Festa del Perdono 7, 20122, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2019.02.007DOI Listing
June 2019

Defining the immunogram of breast cancer: a focus on clinical trials.

Expert Opin Biol Ther 2019 May 1;19(5):383-385. Epub 2019 Apr 1.

a Division of Early Drug Development for Innovative Therapy , IEO, European Institute of Oncology IRCCS , Milan , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1598372DOI Listing
May 2019

Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3β-MCL-1 Axis.

Cancer Cell 2019 May 25;35(5):798-815.e5. Epub 2019 Apr 25.

Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, via Adamello 16, 20139 Milan, Italy; Department of Biosciences, University of Milan, 20100 Milan, Italy. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15356108193015
Publisher Site
http://dx.doi.org/10.1016/j.ccell.2019.03.007DOI Listing
May 2019

Recent advances in triple negative breast cancer: the immunotherapy era.

BMC Med 2019 05 9;17(1):90. Epub 2019 May 9.

Division of Early Drug Development for Innovative Therapy, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12916-019-1326-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507064PMC
May 2019

Peptide vaccines in early breast cancer.

Breast 2019 Apr 7;44:128-134. Epub 2019 Feb 7.

IEO, European Institute of Oncology IRCCS, Milan Italy; University of Milan, Italy. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09609776193002
Publisher Site
http://dx.doi.org/10.1016/j.breast.2019.02.003DOI Listing
April 2019

Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors.

Cancer Treat Rev 2019 Mar 19;74:21-28. Epub 2019 Jan 19.

Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2019.01.006DOI Listing
March 2019

Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer: A Review.

JAMA Oncol 2019 Mar 28. Epub 2019 Mar 28.

Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology, IRCCS Milano, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2019.0034DOI Listing
March 2019

The role of histone deacetylase inhibitors in metastatic breast cancer.

Breast 2019 Feb 6;43:130-134. Epub 2018 Dec 6.

IEO, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Hematology, University of Milano, Milan, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2018.12.001DOI Listing
February 2019

Safety of Novel Targeted Therapies in Oncology.

Drug Saf 2019 02;42(2):157-158

Division of Early Drug Development for Innovative Therapy, IEO, European Institute of Oncology IRCCS, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40264-018-0770-zDOI Listing
February 2019

Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology.

Drug Saf 2019 02;42(2):247-262

Pharmaceutical Consultant, 8 Birchdale, Gerrards Cross, Buckinghamshire, SL9 7JA, UK.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40264-018-0778-4
Publisher Site
http://dx.doi.org/10.1007/s40264-018-0778-4DOI Listing
February 2019

A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer.

Expert Rev Clin Pharmacol 2019 Jan 4;12(1):9-16. Epub 2018 Dec 4.

a Division of Early Drug Development for Innovative Therapies , IEO, European Institute of Oncology, IRCCS Milano , Milano , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1552134DOI Listing
January 2019

Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life.

Crit Rev Oncol Hematol 2019 Jan 26;133:171-182. Epub 2018 Nov 26.

Division of Early Drug Development for Innovative Therapy, IEO, European Institute of Oncology IRCCS, Milan; Department of Oncology and Haematology (DIPO), University of Milan, Milan, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2018.11.008DOI Listing
January 2019

The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients.

Breast 2018 Dec 22;42:41-49. Epub 2018 Aug 22.

Fertility and Procreation Unit, Gynecologic Oncology Department, IRCCS European Institute of Oncology, European School of Oncology (ESO), Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2018.08.099DOI Listing
December 2018

Liver toxicity in the era of immune checkpoint inhibitors: A practical approach.

Crit Rev Oncol Hematol 2018 Dec 3;132:125-129. Epub 2018 Oct 3.

Division of Early Drug Development for Innovative Therapies, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, via Festa del Perdono 7, 20122 Milan, Italy.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10408428183028
Publisher Site
http://dx.doi.org/10.1016/j.critrevonc.2018.09.019DOI Listing
December 2018

Gyneco-oncological genomics and emerging biomarkers for cancer treatment with immune-checkpoint inhibitors.

Semin Cancer Biol 2018 10 27;52(Pt 2):253-258. Epub 2018 May 27.

Division of Early Drug Development, Istituto Europeo di Oncologia, University of Milano, Department of Haematology and Oncology, Via Ripamonti 435, 20141, Milano, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcancer.2018.05.004DOI Listing
October 2018

Talking to patients about biosimilars.

Future Oncol 2018 Oct 1;14(23):2403-2414. Epub 2018 Jun 1.

Pfizer Ltd, Sandwich, Kent, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0044DOI Listing
October 2018

Inflammatory breast cancer and chest wall disease: The oncologist perspective.

Eur J Surg Oncol 2018 08 22;44(8):1142-1147. Epub 2018 May 22.

University of Milano, Department of Oncology and Hemato-Oncology, Division of Early Drug Development for Innovative Therapies, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141 Milano, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejso.2018.05.019DOI Listing
August 2018

Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis.

Eur J Cancer 2018 07 17;97:1-6. Epub 2018 May 17.

Division of New Drug Development, European Institute of Oncology, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.03.023DOI Listing
July 2018

Edoxaban for Cancer-Associated Venous Thromboembolism.

N Engl J Med 2018 07;379(1):93

University of Milan, Milan, Italy

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1806646DOI Listing
July 2018

The PROMISe to increase precision in adjuvant therapy for early breast cancer: To "Type" or to "Print"?

NPJ Breast Cancer 2018 22;4:12. Epub 2018 May 22.

2Department of Hematology and Oncology, European Institute of Oncology, University of Milano, Via Ripamonti 435, 20141 Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41523-018-0064-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964184PMC
May 2018

Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy.

Biomed Res Int 2017 10;2017:4719194. Epub 2017 Jul 10.

Division of Early Drug Development, European Institute of Oncology, Via Ripamonti 435, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/4719194DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5523547PMC
April 2018

A new approach to assess drug sensitivity in cells for novel drug discovery.

Expert Opin Drug Discov 2018 04 7;13(4):339-346. Epub 2018 Feb 7.

a Division of Early Drug Development , European Institute of Oncology , Milano , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2018.1437136DOI Listing
April 2018

Addition of platinum salts to neoadjuvant chemotherapy in triple-negative breast cancer: a new standard of care?

Lancet Oncol 2018 04 28;19(4):434-436. Epub 2018 Feb 28.

Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, 20141 Milan, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30129-3DOI Listing
April 2018

Targeting the microenvironment in solid tumors.

Cancer Treat Rev 2018 Apr 22;65:22-32. Epub 2018 Feb 22.

Division of Early Drug Development for Innovative Therapies, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2018.02.004DOI Listing
April 2018

Cetuximab for treating non-small cell lung cancer.

Expert Opin Biol Ther 2018 04;18(4):483-493

a University of Milano, Department of Oncology and Hemato-Oncology, Division of Early Drug Development for Innovative Therapies , European Institute of Oncology , Milano , Italia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2018.1452906DOI Listing
April 2018

Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer.

Expert Opin Pharmacother 2018 Feb 22;19(3):299-305. Epub 2018 Jan 22.

a Division of Early Drug Development , European Institute of Oncology , Milan , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1429407DOI Listing
February 2018

A rude awakening from tumour cells.

Nature 2018 02;554(7690):35-36

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/d41586-018-01140-zDOI Listing
February 2018

Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients.

Eur J Cancer 2018 01 8;89:49-55. Epub 2017 Dec 8.

European Institute of Oncology, Division of New Drug Development, Italy; Department of Oncology and Hematology, University of Milano, Milano, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.10.034DOI Listing
January 2018

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date.

Breast Cancer (Dove Med Press) 2018 30;10:23-29. Epub 2018 Jan 30.

European Institute of Oncology, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BCTT.S134641DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796458PMC
January 2018

Breast cancer mortality in European Union: An outlook of good news and bad news in a two-speed Europe!

Breast 2017 Dec 19;36:86-88. Epub 2017 Jul 19.

Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2017.07.010DOI Listing
December 2017

Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice.

Biochim Biophys Acta Rev Cancer 2017 Dec 20;1868(2):527-537. Epub 2017 Oct 20.

Ramon y Cajal University Hospital, Ctra. Colmenar Viejo km. 9, 100, 28034 Madrid, Spain; Baselga Institute of Oncology, Madrid, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbcan.2017.10.003DOI Listing
December 2017

Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer.

Eur J Cancer 2017 12 15;87:164-171. Epub 2017 Nov 15.

Division of Early Drug Development, European Institute of Oncology, Milano, Italy; Department of Haematology and Oncology, University of Milano, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.10.011DOI Listing
December 2017

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:
Shona Hendry Roberto Salgado Thomas Gevaert Prudence A Russell Tom John Bibhusal Thapa Michael Christie Koen van de Vijver M V Estrada Paula I Gonzalez-Ericsson Melinda Sanders Benjamin Solomon Cinzia Solinas Gert G G M Van den Eynden Yves Allory Matthias Preusser Johannes Hainfellner Giancarlo Pruneri Andrea Vingiani Sandra Demaria Fraser Symmans Paolo Nuciforo Laura Comerma E A Thompson Sunil Lakhani Seong-Rim Kim Stuart Schnitt Cecile Colpaert Christos Sotiriou Stefan J Scherer Michail Ignatiadis Sunil Badve Robert H Pierce Giuseppe Viale Nicolas Sirtaine Frederique Penault-Llorca Tomohagu Sugie Susan Fineberg Soonmyung Paik Ashok Srinivasan Andrea Richardson Yihong Wang Ewa Chmielik Jane Brock Douglas B Johnson Justin Balko Stephan Wienert Veerle Bossuyt Stefan Michiels Nils Ternes Nicole Burchardi Stephen J Luen Peter Savas Frederick Klauschen Peter H Watson Brad H Nelson Carmen Criscitiello Sandra O'Toole Denis Larsimont Roland de Wind Giuseppe Curigliano Fabrice André Magali Lacroix-Triki Mark van de Vijver Federico Rojo Giuseppe Floris Shahinaz Bedri Joseph Sparano David Rimm Torsten Nielsen Zuzana Kos Stephen Hewitt Baljit Singh Gelareh Farshid Sibylle Loibl Kimberly H Allison Nadine Tung Sylvia Adams Karen Willard-Gallo Hugo M Horlings Leena Gandhi Andre Moreira Fred Hirsch Maria V Dieci Maria Urbanowicz Iva Brcic Konstanty Korski Fabien Gaire Hartmut Koeppen Amy Lo Jennifer Giltnane Marlon C Rebelatto Keith E Steele Jiping Zha Kenneth Emancipator Jonathan W Juco Carsten Denkert Jorge Reis-Filho Sherene Loi Stephen B Fox

Adv Anat Pathol 2017 Nov;24(6):311-335

Departments of *Pathology §§§Medical Oncology, Peter MacCallum Cancer Centre, Melbourne †The Sir Peter MacCallum Department of Oncology Departments of **Pathology ∥∥Medicine, University of Melbourne ¶¶Department of Anatomical Pathology, Royal Melbourne Hospital, Parkville #Department of Anatomical Pathology, St Vincent's Hospital Melbourne, Fitzroy ††Department of Medical Oncology, Austin Health ‡‡Olivia Newton-John Cancer Research Institute, Heidelberg §§School of Cancer Medicine, La Trobe University, Bundoora §§§§§Centre for Clinical Research and School of Medicine, The University of Queensland ∥∥∥∥∥Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane §§§§§§§§§§The Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst ∥∥∥∥∥∥∥∥∥∥Australian Clinical Labs, Bella Vista ‡‡‡‡‡‡‡‡‡‡‡‡Directorate of Surgical Pathology, SA Pathology §§§§§§§§§§§§Discipline of Medicine, Adelaide University, Adelaide, Australia ***********Department of Surgical Oncology, Netherlands Cancer Institute †††††††††††††Department of Pathology ##Divisions of Diagnostic Oncology & Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands ###Université Paris-Est ****INSERM, UMR 955 ††††Département de pathologie, APHP, Hôpital Henri-Mondor, Créteil ∥∥∥∥∥∥∥∥∥Service de Biostatistique et d'Epidémiologie, Gustave Roussy, CESP, Inserm U1018, Université-Paris Sud, Université Paris-Saclay ¶¶¶¶¶¶¶¶¶¶INSERM Unit U981, and Department of Medical Oncology, Gustave Roussy, Villejuif ##########Faculté de Médecine, Université Paris Sud, Kremlin-Bicêtre †††††††Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre ‡‡‡‡‡‡‡University of Auvergne UMR1240, Clermont-Ferrand, France ‡‡‡‡Department of Medicine, Clinical Division of Oncology §§§§Institute of Neurology, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Vienna ††††††††††††††Institute of Pathology, Medical University of Graz, Austria ∥∥∥∥European Institute of Oncology ¶¶¶¶School of Medicine ######Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan ¶¶¶¶¶¶¶¶¶¶¶¶¶Department of Surgery, Oncology and Gastroenterology, University of Padova #############Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy †††††Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona †††††††††††Pathology Department, IIS-Fundacion Jimenez Diaz, UAM, Madrid, Spain §Department of Pathology and TCRU, GZA ¶¶¶Department of Pathology, GZA Ziekenhuizen, Antwerp ∥Laboratory of Experimental Urology, Department of Development and Regeneration, KU Leuven ‡‡‡‡‡‡‡‡‡‡‡Department of Pathology, University Hospital Leuven, Leuven, Belgium ¶Department of Pathology, AZ Klina, Brasschaat ††††††Department of Pathology, GZA Ziekenhuizen, Sint-Augustinus, Wilrijk ∥∥∥Molecular Immunology Unit ‡‡‡‡‡‡Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles ‡Breast Cancer Translational Research Laboratory/Breast International Group, Institut Jules Bordet **************European Organisation for Research and Treatment of Cancer (EORTC) Headquarters *******Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium §§§§§§§Department of Surgery, Kansai Medical School, Hirakata, Japan #######Severance Biomedical Science Institute and Department of Medical Oncology, Yonsei University College of Medicine, Seoul, South Korea ∥∥∥∥∥∥∥∥Tumor Pathology Department, Maria Sklodowska-Curie Memorial Cancer Center ¶¶¶¶¶¶¶¶Institute of Oncology, Gliwice Branch, Gliwice, Poland ‡‡‡‡‡‡‡‡‡‡‡‡‡‡Pathology and Tissue Analytics, Roche Innovation Centre Munich, Penzberg †††††††††Institute of Pathology, Charité Universitätsmedizin Berlin ‡‡‡‡‡‡‡‡‡VMscope GmbH, Berlin ¶¶¶¶¶¶¶¶¶German Breast Group GmbH, Neu-Isenburg, Germany **********Trev & Joyce Deeley Research Centre, British Columbia Cancer Agency ††††††††††Department of Biochemistry and Microbiology, University of Victoria, Victoria Departments of ‡‡‡‡‡‡‡‡‡‡Medical Genetics #########Pathology and Laboratory Medicine ¶¶¶¶¶¶¶¶¶¶¶Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC ###########Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Canada §§§§§§§§§§§Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Doha, Qatar ‡‡‡‡‡‡‡‡Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center §§§§§§§§Warren Alpert Medical School of Brown University, Providence ¶¶¶¶¶National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, PA †††Breast Cancer Research Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Departments of ‡‡‡Pathology, Microbiology and Immunology ########Department of Medicine, Vanderbilt University Medical Centre *********Vanderbilt Ingram Cancer Center, Nashville §§§§§§§§§Department of Pathology, Yale University School of Medicine, New Haven ∥∥∥∥∥∥∥∥∥∥∥Department of Oncology, Montefiore Medical Centre, Albert Einstein College of Medicine ∥∥∥∥∥∥∥Montefiore Medical Center ¶¶¶¶¶¶¶The Albert Einstein College of Medicine, Bronx, NY ********Department of Pathology, Brigham and Women's Hospital #####Cancer Research Institute and Department of Pathology, Beth Israel Deaconess Cancer Center ******Harvard Medical School ¶¶¶¶¶¶¶¶¶¶¶¶Division of Hematology-Oncology, Beth Israel Deaconess Medical Center ††††††††Department of Cancer Biology ‡‡‡‡‡‡‡‡‡‡‡‡‡Dana-Farber Cancer Institute, Boston, MA ∥∥∥∥∥∥∥∥∥∥∥∥∥Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO ‡‡‡‡‡Department of Cancer Biology, Mayo Clinic, Jacksonville, FL ∥∥∥∥∥∥Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN ¶¶¶¶¶¶Cancer Immunotherapy Trials Network, Central Laboratory and Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA ††††††††††††Department of Pathology, New York University Langone Medical Centre ############New York University Medical School *************Perlmutter Cancer Center §§§§§§§§§§§§§Pulmonary Pathology, New York University Center for Biospecimen Research and Development, New York University ***************Department of Pathology, Memorial Sloan-Kettering Cancer Center ####Departments of Radiation Oncology and Pathology, Weill Cornell Medicine, New York, NY *****Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX ∥∥∥∥∥∥∥∥∥∥∥∥Pathology Department, Stanford University Medical Centre, Stanford ∥∥∥∥∥∥∥∥∥∥∥∥∥∥Department of Pathology, Stanford University, Palo Alto ***Department of Pathology, School of Medicine, University of California, San Diego §§§§§§§§§§§§§§Research Pathology, Genentech Inc., South San Francisco, CA *************Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda ¶¶¶¶¶¶¶¶¶¶¶¶¶¶Translational Sciences, MedImmune, Gaithersberg, MD §§§§§§Academic Medical Innovation, Novartis Pharmaceuticals Corporation, East Hanover ##############Translational Medicine, Merck & Co. Inc., Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAP.0000000000000161DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638696PMC
November 2017

Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting.

Curr Opin Oncol 2017 Nov;29(6):428-433

Division of Experimental Therapeutics, European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000401DOI Listing
November 2017

Notch inhibitors and their role in the treatment of triple negative breast cancer: promises and failures.

Curr Opin Oncol 2017 Nov;29(6):411-427

New Drugs Development Division, European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000406DOI Listing
November 2017

Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies.

Eur J Cancer 2017 11 19;86:257-265. Epub 2017 Oct 19.

Department of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, 34129 Trieste, Italy; Breast Cancer Unit and Translational Research Unit, ASST Cremona, Viale Concordia 1, 26100 Cremona, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.09.018DOI Listing
November 2017

Evaluation of inter-observer variability according to RECIST 1.1 and its influence on response classification in CT measurement of liver metastases.

Eur J Radiol 2017 Oct 4;95:96-101. Epub 2017 Aug 4.

Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, University of Pavia and Division of Radiology, National Center of Oncological Hadrontherapy (CNAO Foundation), Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejrad.2017.08.001DOI Listing
October 2017

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.

Authors:
Shona Hendry Roberto Salgado Thomas Gevaert Prudence A Russell Tom John Bibhusal Thapa Michael Christie Koen van de Vijver M V Estrada Paula I Gonzalez-Ericsson Melinda Sanders Benjamin Solomon Cinzia Solinas Gert G G M Van den Eynden Yves Allory Matthias Preusser Johannes Hainfellner Giancarlo Pruneri Andrea Vingiani Sandra Demaria Fraser Symmans Paolo Nuciforo Laura Comerma E A Thompson Sunil Lakhani Seong-Rim Kim Stuart Schnitt Cecile Colpaert Christos Sotiriou Stefan J Scherer Michail Ignatiadis Sunil Badve Robert H Pierce Giuseppe Viale Nicolas Sirtaine Frederique Penault-Llorca Tomohagu Sugie Susan Fineberg Soonmyung Paik Ashok Srinivasan Andrea Richardson Yihong Wang Ewa Chmielik Jane Brock Douglas B Johnson Justin Balko Stephan Wienert Veerle Bossuyt Stefan Michiels Nils Ternes Nicole Burchardi Stephen J Luen Peter Savas Frederick Klauschen Peter H Watson Brad H Nelson Carmen Criscitiello Sandra O'Toole Denis Larsimont Roland de Wind Giuseppe Curigliano Fabrice André Magali Lacroix-Triki Mark van de Vijver Federico Rojo Giuseppe Floris Shahinaz Bedri Joseph Sparano David Rimm Torsten Nielsen Zuzana Kos Stephen Hewitt Baljit Singh Gelareh Farshid Sibylle Loibl Kimberly H Allison Nadine Tung Sylvia Adams Karen Willard-Gallo Hugo M Horlings Leena Gandhi Andre Moreira Fred Hirsch Maria V Dieci Maria Urbanowicz Iva Brcic Konstanty Korski Fabien Gaire Hartmut Koeppen Amy Lo Jennifer Giltnane Marlon C Rebelatto Keith E Steele Jiping Zha Kenneth Emancipator Jonathan W Juco Carsten Denkert Jorge Reis-Filho Sherene Loi Stephen B Fox

Adv Anat Pathol 2017 Sep;24(5):235-251

Departments of *Pathology §§§Medical Oncology, Peter MacCallum Cancer Centre, Melbourne †The Sir Peter MacCallum Department of Oncology Departments of **Pathology ∥∥Medicine, University of Melbourne ¶¶Department of Anatomical Pathology, Royal Melbourne Hospital, Parkville #Department of Anatomical Pathology, St Vincent's Hospital Melbourne, Fitzroy ††Department of Medical Oncology, Austin Health ‡‡Olivia Newton-John Cancer Research Institute, Heidelberg §§School of Cancer Medicine, La Trobe University, Bundoora §§§§§Centre for Clinical Research and School of Medicine, The University of Queensland ∥∥∥∥∥Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane §§§§§§§§§§The Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst ∥∥∥∥∥∥∥∥∥∥Australian Clinical Labs, Bella Vista ‡‡‡‡‡‡‡‡‡‡‡‡Directorate of Surgical Pathology, SA Pathology §§§§§§§§§§§§Discipline of Medicine, Adelaide University, Adelaide, Australia ***********Department of Surgical Oncology, Netherlands Cancer Institute †††††††††††††Department of Pathology ##Divisions of Diagnostic Oncology & Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands ###Université Paris-Est ****INSERM, UMR 955 ††††Département de pathologie, APHP, Hôpital Henri-Mondor, Créteil ∥∥∥∥∥∥∥∥∥Service de Biostatistique et d'Epidémiologie, Gustave Roussy, CESP, Inserm U1018, Université-Paris Sud, Université Paris-Saclay ¶¶¶¶¶¶¶¶¶¶INSERM Unit U981, and Department of Medical Oncology, Gustave Roussy, Villejuif ##########Faculté de Médecine, Université Paris Sud, Kremlin-Bicêtre †††††††Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre ‡‡‡‡‡‡‡University of Auvergne UMR1240, Clermont-Ferrand, France ‡‡‡‡Department of Medicine, Clinical Division of Oncology §§§§Institute of Neurology, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Vienna ††††††††††††††Institute of Pathology, Medical University of Graz, Austria ∥∥∥∥European Institute of Oncology ¶¶¶¶School of Medicine ######Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan ¶¶¶¶¶¶¶¶¶¶¶¶¶Department of Surgery, Oncology and Gastroenterology, University of Padova #############Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy †††††Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona †††††††††††Pathology Department, IIS-Fundacion Jimenez Diaz, UAM, Madrid, Spain §Department of Pathology and TCRU, GZA ¶¶¶Department of Pathology, GZA Ziekenhuizen, Antwerp ∥Laboratory of Experimental Urology, Department of Development and Regeneration, KU Leuven ‡‡‡‡‡‡‡‡‡‡‡Department of Pathology, University Hospital Leuven, Leuven, Belgium ¶Department of Pathology, AZ Klina, Brasschaat ††††††Department of Pathology, GZA Ziekenhuizen, Sint-Augustinus, Wilrijk ∥∥∥Molecular Immunology Unit ‡‡‡‡‡‡Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles ‡Breast Cancer Translational Research Laboratory/Breast International Group, Institut Jules Bordet **************European Organisation for Research and Treatment of Cancer (EORTC) Headquarters *******Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium §§§§§§§Department of Surgery, Kansai Medical School, Hirakata, Japan #######Severance Biomedical Science Institute and Department of Medical Oncology, Yonsei University College of Medicine, Seoul, South Korea ∥∥∥∥∥∥∥∥Tumor Pathology Department, Maria Sklodowska-Curie Memorial Cancer Center ¶¶¶¶¶¶¶¶Institute of Oncology, Gliwice Branch, Gliwice, Poland ‡‡‡‡‡‡‡‡‡‡‡‡‡‡Pathology and Tissue Analytics, Roche Innovation Centre Munich, Penzberg †††††††††Institute of Pathology, Charité Universitätsmedizin Berlin ‡‡‡‡‡‡‡‡‡VMscope GmbH, Berlin ¶¶¶¶¶¶¶¶¶German Breast Group GmbH, Neu-Isenburg, Germany **********Trev & Joyce Deeley Research Centre, British Columbia Cancer Agency ††††††††††Department of Biochemistry and Microbiology, University of Victoria, Victoria Departments of ‡‡‡‡‡‡‡‡‡‡Medical Genetics #########Pathology and Laboratory Medicine ¶¶¶¶¶¶¶¶¶¶¶Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC ###########Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Canada §§§§§§§§§§§Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Doha, Qatar ‡‡‡‡‡‡‡‡Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center §§§§§§§§Warren Alpert Medical School of Brown University, Providence ¶¶¶¶¶National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, PA †††Breast Cancer Research Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Departments of ‡‡‡Pathology, Microbiology and Immunology ########Department of Medicine, Vanderbilt University Medical Centre *********Vanderbilt Ingram Cancer Center, Nashville §§§§§§§§§Department of Pathology, Yale University School of Medicine, New Haven ∥∥∥∥∥∥∥∥∥∥∥Department of Oncology, Montefiore Medical Centre, Albert Einstein College of Medicine ∥∥∥∥∥∥∥Montefiore Medical Center ¶¶¶¶¶¶¶The Albert Einstein College of Medicine, Bronx, NY ********Department of Pathology, Brigham and Women's Hospital #####Cancer Research Institute and Department of Pathology, Beth Israel Deaconess Cancer Center ******Harvard Medical School ¶¶¶¶¶¶¶¶¶¶¶¶Division of Hematology-Oncology, Beth Israel Deaconess Medical Center ††††††††Department of Cancer Biology ‡‡‡‡‡‡‡‡‡‡‡‡‡Dana-Farber Cancer Institute, Boston, MA ∥∥∥∥∥∥∥∥∥∥∥∥∥Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO ‡‡‡‡‡Department of Cancer Biology, Mayo Clinic, Jacksonville, FL ∥∥∥∥∥∥Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN ¶¶¶¶¶¶Cancer Immunotherapy Trials Network, Central Laboratory and Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA ††††††††††††Department of Pathology, New York University Langone Medical Centre ############New York University Medical School *************Perlmutter Cancer Center §§§§§§§§§§§§§Pulmonary Pathology, New York University Center for Biospecimen Research and Development, New York University ***************Department of Pathology, Memorial Sloan-Kettering Cancer Center ####Departments of Radiation Oncology and Pathology, Weill Cornell Medicine, New York, NY *****Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX ∥∥∥∥∥∥∥∥∥∥∥∥Pathology Department, Stanford University Medical Centre, Stanford ∥∥∥∥∥∥∥∥∥∥∥∥∥∥Department of Pathology, Stanford University, Palo Alto ***Department of Pathology, School of Medicine, University of California, San Diego §§§§§§§§§§§§§§Research Pathology, Genentech Inc., South San Francisco, CA *************Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda ¶¶¶¶¶¶¶¶¶¶¶¶¶¶Translational Sciences, MedImmune, Gaithersberg, MD §§§§§§Academic Medical Innovation, Novartis Pharmaceuticals Corporation, East Hanover ##############Translational Medicine, Merck & Co. Inc., Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAP.0000000000000162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564448PMC
September 2017

Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer.

J Clin Oncol 2017 Aug 29;35(23):2600-2603. Epub 2017 Jun 29.

Giuseppe Curigliano and Carmen Criscitiello, Istituto Europeo di Oncologia, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.5960DOI Listing
August 2017

Entinostat for the treatment of breast cancer.

Expert Opin Investig Drugs 2017 Aug 24;26(8):965-971. Epub 2017 Jul 24.

a Division of Early Drug Development , European Institute of Oncology , Milan , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2017.1353077DOI Listing
August 2017

How to Achieve Optimal Care in Early Breast Cancer with 'Less' or 'More' Treatment.

Breast Care (Basel) 2017 Jul 27;12(3):136-137. Epub 2017 Jun 27.

Division of Early Drug Development for Innovative Therapies, Istituto Europeo di Oncologia, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000478652DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527166PMC
July 2017

Extended Adjuvant Chemotherapy in Triple-Negative Breast Cancer.

Breast Care (Basel) 2017 Jul 27;12(3):152-158. Epub 2017 Jun 27.

Cancer Institute Ion Chiricuta, Cluj-Napoca, Romania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000478087DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527164PMC
July 2017

Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer.

Expert Opin Drug Metab Toxicol 2017 May 21;13(5):575-581. Epub 2017 Apr 21.

a Early Drugs Development for Innovative Therapies Division , European Institute of Oncology , Milan , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17425255.2017.1318848DOI Listing
May 2017

The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials.

Eur J Cancer 2017 04 24;75:245-258. Epub 2017 Feb 24.

Department of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, 34129 Trieste, Italy; Unit of Molecular Therapy and Pharmacogenomic, ASST Cremona, Viale Concordia 1, 26100 Cremona, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.01.026DOI Listing
April 2017

Over-using chemotherapy in the adjuvant setting.

Breast 2017 Feb 17;31:303-308. Epub 2016 Nov 17.

Division of Pathology, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141 Milano, Italy; University of Milan, Breast Cancer Program, Via Ripamonti 435, 20133 Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2016.11.011DOI Listing
February 2017

The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations.

Curr Oncol Rep 2017 Jan;19(1)

Division of Experimental Cancer Medicine, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141+, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-017-0564-yDOI Listing
January 2017

Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer.

Cancer Treat Rev 2016 Nov 6;50:205-207. Epub 2016 Oct 6.

Istituto Europeo di Oncologia, Via Ripamonti 435, 20141 Milano, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2016.09.019DOI Listing
November 2016

Being more precise in assessing the value of precision medicine in breast cancer.

Breast 2016 Oct;29:186-7

Division of Experimental Cancer Medicine, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141 Milano, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2016.08.010DOI Listing
October 2016

Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond.

Ther Adv Med Oncol 2016 Sep 10;8(5):360-74. Epub 2016 Jul 10.

Division of Experimental Therapeutics, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141 Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834016658423DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4981297PMC
September 2016

Biosimilars: Extrapolation for oncology.

Crit Rev Oncol Hematol 2016 Aug 15;104:131-7. Epub 2016 Jun 15.

Pfizer Inc., 235 East 42nd Street, New York, NY 10017-5755, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2016.06.002DOI Listing
August 2016

HER2 Equivocal Status in Early Breast Cancer Is Not Associated with Higher Risk of Recurrence.

Anticancer Res 2016 Jul;36(7):3537-40

Division of Experimental Therapeutics, University of Milan-Bicocca, Milan, Italy

View Article

Download full-text PDF

Source
July 2016

Future perspectives in cancer immunotherapy.

Ann Transl Med 2016 Jul;4(14):273

Division of Experimental Therapeutics, European Institute of Oncology, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2016.07.14DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971381PMC
July 2016